ArticleFrontiers in oncology2026
Clinicopathologic features and integrated outcome analysis of pediatric and young adult salivary secretory carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Salivary secretory carcinoma (SSC) is a rare salivary gland malignancy characterized by recurrent ETV6-related gene fusions and generally classified as low grade. However, age-specific outcome data in pediatric and young adult patients remain limited. The present study aimed to characterize clinicopathologic features and clinical outcomes of SSC in younger patients and to contextualize these findings through an integrated analysis of published cases. Methods: We retrospectively analyzed 35 patients with SSC treated at a single institution between 2019 and 2023, including 11 individuals aged ≤29 years. Clinical, histopathologic, immunohistochemical, molecular, and outcome data were evaluated. A focused literature search identified 47 eligible publications comprising 83 reported pediatric and young adult cases, which were incorporated into a descriptive integrated analysis. Results: all younger patients presented with parotid tumors and exhibited a higher median Ki-67 labeling index compared with older patients (15.0% vs 7.5%). Among 50 evaluable published cases, recurrence occurred in 9 patients, corresponding to a pooled recurrence rate of 18.0% (95% CI 7.4-28.6%). Lymph node metastasis was documented in 10.0% of evaluable cases. The recurrence rate observed in our young subgroup (18.2%) was consistent with pooled estimates. Conclusions: SSC in pediatric and young adult patients may demonstrate a broader biological spectrum than traditionally assumed. Although generally considered low grade, a measurable subset of younger patients exhibits recurrent or metastatic behavior, underscoring the importance of systematic outcome assessment in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.